Drug and asset intelligence for Deucravacitinib with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 1
Stage: Development stage unavailable

Recent signals(2)

ClinicalAugust 3, 2026

Deucravacitinib Shows Promise in Treating Psoriasis with Eczematous Features

A study is evaluating the efficacy and safety of deucravacitinib in patients with Psoriasis Eczema (PsEma) over 16 weeks.

ClinicalJune 22, 2026

Deucravacitinib shows promise in Pityriasis Rubra Pilaris study by Mayo Clinic

A study is underway to evaluate the safety and effectiveness of Deucravacitinib in patients with Pityriasis Rubra Pilaris.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

— Deucravacitinib

June 22, 2026 · N/A

Indications

Psoriasis and Eczema →

Therapeutic areas

Dermatology →

Dermatology · Small Molecule →

Psoriasis and Eczema →

Small Molecule →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.